January 12,Zhangjiang Pharma Valley Enterprise Oricell TherapeuticsAnnounces Completion of $70 Million Series C1 Financing. This round of financing was led by Beijing Municipal Medical and Health Industry Investment Fund, Qiming Venture Capital, and a globally leading healthcare fund. Other investors include an international sovereign fund, NGS (Australian pension fund), Yizhuang Guotou, Licheng Investment, Ruifeng Capital, and more. This USD financing will accelerate Oricell Therapeutics' internationalization and clinical development process, strengthen its technological capabilities in the cell therapy field, and enhance the value of its industrialization pipeline.
Qrigincell Therapeutics is committed to developing CAR-T cell therapies with global clinical value, and has generated proof-of-concept (POC) clinical data from multiple pipelines. Ori-C101, a CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC), has completed Phase I investigator-initiated clinical research and Phase I registered clinical trials, and is about to initiate pivotal Phase II clinical trials. The available clinical data demonstrate excellent efficacy and safety, and have been presented at several top international academic conferences such as ASCO. This product is expected to become the world's first approved CAR-T therapy for hepatocellular carcinoma.
At the same time, multiple next-generation multi-target and multi-mechanism CAR-T products are being developed on Qrigincell Therapeutics' full platform. Its innovative secretory CAR-T product, OriC902, has achieved breakthrough efficacy in end-stage solid tumor patients. The company’s self-developed dual-target in vivo CAR-T product has initiated exploratory clinical research, validating the technical potential of “off-the-shelf CAR-T” – directly generating CAR-T cells within the patient's body, significantly enhancing the accessibility of cellular therapies.
